The Roundhill GLP-1 & Weight Loss ETF (OZEM) has experienced notable insider buying activity, with 15.9% of its weighted holdings seeing purchases by insiders in the past six months. Specifically, Eli Lilly (LLY), which represents 15.90% of OZEM and is its second-largest holding, recorded eight directors and officers acquiring shares during this period, signaling strong internal confidence in the company's prospects.
The Roundhill GLP-1 & Weight Loss ETF (OZEM) exhibits significant insider buying activity, with 15.9% of its weighted underlying holdings experiencing insider purchases within the last six months. This strong internal conviction is primarily driven by Eli Lilly (LLY), which constitutes 15.90% of OZEM and is its second-largest holding. The concentration of insider buying in a core component of the ETF signals robust confidence in the GLP-1 and weight loss sector's prospects. Eight directors and officers at Eli Lilly executed share purchases in August 2025, according to recent Form 4 data. Notable transactions include President, Chair, and CEO David A. Ricks acquiring 1,632 shares at $644.77, and EVP & CFO Lucas Montarce purchasing 715 shares at $691.79. These transactions, totaling significant value, occurred at prices ranging from $634.40 to $691.79, notably below LLY's last reported trade price of $826.41. The substantial insider buying at LLY, a key player in the GLP-1 market, indicates a strong bullish sentiment from those with the most intimate knowledge of the company's operations and future pipeline. This activity suggests insiders believe the stock is undervalued at their purchase prices or that significant upside potential exists. The overall sentiment for LLY is rated 0.8 (very positive), contributing to a strongly positive general sentiment (0.75) for the related ETF and sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
